Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) is a pivotal chemokine regulating the migration and infiltration of monocytes, macrophages, and memory T cells. It plays a critical role in chronic inflammatory diseases, fibrotic disorders, and tumor microenvironment (TME) immunosuppression.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CCL2/MCP-1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCL2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native post-translational modifications. |
View CCL2 Products |
| Gene Delivery | CCR2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Ideal for GPCR functional assays. |
View CCR2 Products |
| Benchmark Ab | Anti-CCL2 Recombinant Antibody Sequence of Carlumab (CNTO 888). Recombinant positive control for neutralization assays. |
View CCL2 Products |
| Validator | CCL2 siRNA Set For target knockdown verification in cellular models. |
View CCL2 Products |
| Related Target A | CCR2 Primary G-protein coupled receptor for CCL2, mediating monocyte chemotaxis. |
View CCR2 Products |
| Related Target B | CXCL12 Synergistic chemokine target frequently co-expressed in inflammatory and tumor microenvironments. |
View CXCL12 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Chemokine Dimerization & Aggregation | Sequence-verified, carrier-free recombinant proteins with verified monomeric/dimeric state consistency. |
| Receptor Activation (GPCR) Screening | Lentiviral particles for stable CCR2 overexpressing cell lines, preserving native 7-transmembrane conformation. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives / Off-Target Effects | Validated siRNA sets included for target specificity verification. |
Live CCL2/MCP-1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the CCL2/MCP-1 axis remains a highly attractive yet challenging frontier in immunology and oncology. CCL2 is a key chemokine recruiting immunosuppressive myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) to the tumor microenvironment, while driving inflammatory cascades in fibrosis and autoimmune diseases. The race for CCL2 therapeutics is intensifying, with major players shifting focus from traditional systemic mAbs to bispecific antibodies and combination regimens that can overcome the "chemokine sink" effect.
As first-generation therapies reach the clinic, the next wave of R&D is targeting multi-chemokine blockades and dual receptor antagonists to prevent compensatory pathway activation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Johnson & Johnson, Roche | Solid Tumors, Inflammatory Fibrosis | Neutralization Assay (Need high-purity, endotoxin-controlled CCL2 protein) |
| Bispecific Antibodies | Innovent Biologics, Akeso | Immuno-oncology (TME modulation) | Dual-binding verification (Need cross-species reactive CCL2 and partner antigens) |
| Small Molecule Antagonists | ChemoCentryx, Bristol Myers Squibb | Diabetic Nephropathy, Autoimmune | Receptor binding competition (Need CCR2-expressing stable cell lines via Lentivirus) |